Clinical Trials of Multivalent Opioid Vaccine Components
NCT04458545
Recruiting
Currently, abuse of prescription opioid analgesics and heroin is a serious problem in the U.S. Although several medications, including methadone, buprenorphine, and naltrexone, are available and effective in treating opioid use disorder (OUD), long-term relapse rates remain high. The current study is designed to examine a new approach to treating OUD, namely use of a vaccine targeted against oxycodone \[Oxy(Gly)4-sKLH\], one of the most commonly abused prescription opioids. The vaccination appro... Read More
Gender:
ALL
Ages:
Between 18 years and 59 years
Trial Updated:
05/07/2025
Locations: Clinilabs Drug Development Corporation, Eatontown, New Jersey +1 locations
Conditions: Opioid-use Disorder
Register for Updates
A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
NCT04554914
Recruiting
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.
Gender:
ALL
Ages:
All
Trial Updated:
05/07/2025
Locations: University of California Los Angeles (UCLA) (Adults and Pediatrics), LOS Angeles, California +39 locations
Conditions: Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)
Register for Updates
Cannabidiol in Opioid Use Disorder and Chronic Pain
NCT04587791
Recruiting
This is a double-blind, randomized, placebo-controlled cross-over human laboratory study with a duration of approximately 4 weeks, during which participants will come to the testing site for a total of five times: one initial screening session, and four experimental sessions where study medication, Cannabidiol (CBD) will be administered, separated by at least 72 hours to limit carryover effects.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/07/2025
Locations: Department of Veterans Affairs Hospital, West Haven, Connecticut
Conditions: Chronic Pain, Opioid Use Disorder
Register for Updates
Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT
NCT04678154
Recruiting
The proposed study is a multi-center, prospective randomized controlled trial comparing current standard of care treatment to the SEXTANT treatment protocol in patients with Type III open fractures of the tibia and IIIB fractures of the ankle and hindfoot.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
05/07/2025
Locations: Stanford University, Redwood City, California +30 locations
Conditions: Post Operative Surgical Site Infection
Register for Updates
Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant
NCT04678427
Recruiting
This clinical trial studies how well an exercise program (Totally Excited About Moving, Mobility, and Exercise \[TEAM Me\]) affects the exercise and dietary habits of pediatric and adolescents and young adults with cancer undergoing a blood stem cell transplant. TEAM Me is an exercise program that reinforces behavior, such as walking and other activities, using "tokens" (i.e. stickers) that can be redeemed for rewards. Participating in the exercise program may result in increased physical fitnes... Read More
Gender:
ALL
Ages:
Between 6 years and 29 years
Trial Updated:
05/07/2025
Locations: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas +1 locations
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Register for Updates
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
NCT04801797
Recruiting
This research is being done to assess the therapeutic activity of a promising combination (azacitidine and venetoclax) versus conventional cytotoxic chemotherapy in induction-eligible patients with acute myeloid leukemia. This study involves the following: * Venetoclax and azacitidine (investigational combination) * Cytarabine and idarubicin or daunorubicin (per standard of care) or Liposomal daunorubicin and cytarabine (per standard of care)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: City of Hope, Duarte, California +8 locations
Conditions: Acute Myeloid Leukemia
Register for Updates
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04895241
Recruiting
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care medications. These may include antimalarials, steroids, and immunosuppressants. The main objective of the study is to learn about the effect litifilimab has on lowering the activity of the disease. The main question researchers want to answer is: -... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Tilda Research Birmingham, Homewood, Alabama +168 locations
Conditions: Lupus Erythematosus, Systemic
Register for Updates
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
NCT04915183
Recruiting
Background: Cisplatin is used to treat head and neck cancer. People who take this drug are at risk for hearing loss. Atorvastatin is a drug used to treat high cholesterol. It might reduce the risk of cisplatin-induced hearing loss. Objective: To find out if atorvastatin reduces hearing loss in people treated with cisplatin and radiation. Eligibility: People ages 18 and older with squamous cell carcinoma of the head and neck who will undergo treatment with cisplatin-based chemotherapy and ra... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/07/2025
Locations: Winship Cancer Institute at Emory University, Atlanta, Georgia +3 locations
Conditions: Hearing Loss, Head and Neck Cancer
Register for Updates
Economic Incentives and vDOT for Latent Tuberculosis Infection
NCT05022862
Recruiting
The purpose of this study is to evaluate a novel and scalable intervention that combines Video Directly Observed Therapy (vDOT) and financial incentives to promote completion of treatment for latent tuberculosis. Adult participants who are initiating treatment for latent tuberculosis will be recruited from the Baltimore City Health Department. The primary hypothesis is that the incentive intervention will increase the percentage of participants that complete the treatment for latent tuberculosis... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Baltimore City Health Department, and Baltimore metropolitan area clinics and health departments, Baltimore, Maryland
Conditions: Latent Tuberculosis
Register for Updates
Primary Care Implementation and Evaluation of Coach McLungs
NCT05059210
Recruiting
The goal of this study is to evaluate the implementation of the Coach McLungsSM shared decision making (SDM) intervention into primary care across a large healthcare system. Coach McLungsSM is a virtual evidence-based asthma intervention with built-in asthma education and clinical decision support. All asthma patients aged 5-17 who attend these practices will be assessed for uncontrolled asthma. Asthma exacerbations attributed to emergency department visits, hospitalizations, and oral steroid us... Read More
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
05/07/2025
Locations: Atrium Health, Charlotte, North Carolina
Conditions: Asthma
Register for Updates
UNC Childhood, Adolescent, and Young Adult Cancer Cohort
NCT05096923
Recruiting
Purpose: This study aims to create a registry of childhood, adolescent, and young adult patients with cancer (\<40 years-old at cancer diagnosis), entitled the 'UNC Childhood, Adolescent, and Young Adult Cancer Cohort' (UNC-CAYACC). This resource will serve to support cancer outcomes research among pediatric and young adult cancer patients with a primary focus on enrolling patients treated as adolescents or young adults (AYAs, 15-39 years). Procedures: As appropriate for age, participants will... Read More
Gender:
ALL
Ages:
Between 1 year and 39 years
Trial Updated:
05/07/2025
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Pediatric Cancer, Cancer, Cancer Metastatic, Survivorship
Register for Updates
Effectiveness of Remote Ischemic Preconditioning for Prevention of Contrast Induced Acute Kidney Injury in Patients Undergoing Coronary Angiograms.
NCT05147831
Recruiting
The use of imaging is increasing in clinical practice, either for diagnosis or intervention. In these imaging processes, contrast medium (CM) is widely used. However, CM administration can induce contrast-induced nephropathy (CI-AKI). CI-AKI is the third most common cause of renal insufficiency, and its incidence varies from 2% to 50% depending on patient risk factors; in addition, studies have shown that CI-AKI occurs in 2% to 25% of patients undergoing coronary intervention. CI-AKI is associat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: University of Texas- Medical Branch (UTMB), Galveston, Texas
Conditions: Contrast-induced Acute Kidney Injury (CI-AKI) Following Coronary Angiogram (CI-AKI), Contrast-induced Nephropathy Following Coronary Angiogram (CIN)
Register for Updates